Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

SHA:600535 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,385	8,468	8,636	8,606	7,898	13,505
Other Revenue	29.81	29.81	37.71	31.19	53.86	70.82
Revenue	8,415	8,498	8,674	8,637	7,952	13,576
Revenue Growth (YoY)	-2.76%	-2.03%	0.42%	8.62%	-41.43%	-28.54%
Cost of Revenue	2,786	2,810	2,885	3,147	2,682	8,115
Gross Profit	5,628	5,688	5,789	5,490	5,269	5,461
Selling, General & Admin	3,388	3,334	3,326	3,267	3,339	3,215
Research & Development	802.65	830.07	917.27	845.34	579.53	689.33
Other Operating Expenses	87.54	87.98	96.46	37.96	110.64	104.05
Operating Expenses	4,290	4,252	4,348	4,149	4,027	4,073
Operating Income	1,339	1,436	1,441	1,341	1,243	1,388
Interest Expense	-61.28	-61.28	-82.52	-64.86	-77.39	-286.69
Interest & Investment Income	91.05	91.05	107.55	107.55	1,792	241.04
Currency Exchange Gain (Loss)	-1.07	-1.07	-1.23	-1.61	7.27	5.58
Other Non Operating Income (Expenses)	-1.63	-3.52	-4.73	-71.11	0	-11.05
EBT Excluding Unusual Items	1,366	1,461	1,460	1,311	2,965	1,337
Impairment of Goodwill	-15.88	-15.88	-	-151.2	-	-59.01
Gain (Loss) on Sale of Investments	-11.59	-213.45	-282.81	-1,125	-79.88	118.21
Gain (Loss) on Sale of Assets	9.1	2.11	0.15	-4.93	41.27	-5.67
Asset Writedown	-203.28	-202.13	-1.78	-194.64	-262.53	-
Other Unusual Items	36.78	36.78	45.51	-1.96	60.04	66.91
Pretax Income	1,181	1,069	1,221	-167.63	2,724	1,457
Income Tax Expense	184.94	209.63	204.46	180.82	315.92	367.2
Earnings From Continuing Operations	995.82	859.06	1,017	-348.46	2,408	1,090
Minority Interest in Earnings	72.16	96.53	54.43	84.22	-48.75	36.03
Net Income	1,068	955.59	1,071	-264.24	2,359	1,126
Net Income to Common	1,068	955.59	1,071	-264.24	2,359	1,126
Net Income Growth	4.06%	-10.78%	-	-	109.51%	12.43%
Shares Outstanding (Basic)	1,486	1,494	1,488	1,468	1,502	1,501
Shares Outstanding (Diluted)	1,486	1,494	1,488	1,468	1,502	1,501
Shares Change (YoY)	-0.28%	0.43%	1.34%	-2.29%	0.08%	-1.06%
EPS (Basic)	0.72	0.64	0.72	-0.18	1.57	0.75
EPS (Diluted)	0.72	0.64	0.72	-0.18	1.57	0.75
EPS Growth	4.35%	-11.16%	-	-	109.33%	13.64%
Free Cash Flow	1,298	1,450	1,907	1,875	2,229	1,382
Free Cash Flow Per Share	0.87	0.97	1.28	1.28	1.48	0.92
Dividend Per Share	0.530	0.530	0.330	0.330	0.330	0.330
Dividend Growth	60.61%	60.61%	-	-	-	-
Gross Margin	66.89%	66.94%	66.74%	63.56%	66.27%	40.23%
Operating Margin	15.91%	16.90%	16.61%	15.52%	15.63%	10.22%
Profit Margin	12.69%	11.24%	12.35%	-3.06%	29.66%	8.29%
Free Cash Flow Margin	15.42%	17.06%	21.98%	21.71%	28.04%	10.18%
EBITDA	1,735	1,832	1,946	1,774	1,648	1,927
EBITDA Margin	20.62%	21.56%	22.43%	20.54%	20.72%	14.20%
D&A For EBITDA	396.65	396.34	504.91	433.92	405.08	539.67
EBIT	1,339	1,436	1,441	1,341	1,243	1,388
EBIT Margin	15.91%	16.90%	16.61%	15.52%	15.63%	10.22%
Effective Tax Rate	15.66%	19.62%	16.74%	-	11.60%	25.20%
Revenue as Reported	8,415	8,498	8,674	8,637	-	13,576

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.